Study guide
6.2 Release Testing: Sterility (USP <71>), Endotoxin (USP <85>) & Particulates (USP <788>)
BCSCP Board Certified Sterile Compounding Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview, USP Standards & CSP Categories
1.1 BCSCP Exam Format, Eligibility, Scoring & 2024 Content Outline 1.2 USP <797> Scope, Core Philosophy & Regulatory Framework 1.3 USP <797> Categories 1, 2, and 3 CSP Classification 1.4 Immediate-Use CSPs: The 4-Hour Rule and Its Conditions
2 Chapter 2: Facilities, Engineering Controls & Cleaning
2.1 Cleanroom Architecture & ISO Classifications 2.2 Primary Engineering Controls (PECs) & Laminar Airflow Dynamics 2.3 Segregated Compounding Areas (SCAs) & Containment SCAs (C-SCAs) 2.4 HVAC Engineering Controls, Pressure Differentials & Air Exchange 2.5 Equipment & Materials in Classified Areas Under Dynamic Conditions 2.6 Cleaning, Disinfecting, Sporicidal Agents & Sterile 70% IPA 2.7 Contingency Planning: Power, HVAC, Supply and Staffing Failures
3 Chapter 3: Environmental Monitoring & Facility Certification
3.1 Viable Airborne Microbial Monitoring 3.2 Total Airborne Non-Viable Particle Counting & Cleanroom Certification Standards 3.3 Surface Microbial Sampling: Contact Plates, Swabs, Incubation Protocols & Action Levels 3.4 Environmental Sampling Excursions, Trend Analysis, and Remediation Protocols
4 Chapter 4: Hand Hygiene, Garbing & Aseptic Technique
4.1 Hand Hygiene & Cleansing Protocols 4.2 Step-by-Step Garbing Sequence & Ante-Room Logistics 4.3 Direct Compounding Area (DCA) Aseptic Technique & First Air Integrity
5 Chapter 5: Beyond-Use Dating, Storage & Container Rules
5.1 Category 1 Beyond-Use Dating & Storage Limitations 5.2 Category 2 Beyond-Use Dating: Sterile vs. Nonsterile Starting Components 5.3 Category 3 Beyond-Use Dating: Requirements for Extended Dating (60/90/120 Days) 5.4 Container Types, Puncture Limits & Multi-Dose Container Rules
6 Chapter 6: Sterilization, Release Testing & Hazardous Drug Compounding
6.1 Terminal Sterilization vs. Sterilizing Filtration 6.2 Release Testing: Sterility (USP <71>), Endotoxin (USP <85>) & Particulates (USP <788>) 6.3 Container Closure Integrity Testing (CCIT) & Visual Inspection 6.4 USP <800> Hazardous Drug Compounding & Closed System Drug-Transfer Devices (CSTDs)
7 Chapter 7: Materials, Equipment & Compounding Workflow
7.1 Compounding Equipment & Technology: ACDs, Balances, Pumps & IV Workflow Systems 7.2 Compounding Supplies, Containers & Closures 7.3 Component Receipt, Storage & Material Transfer 7.4 Calibration, Verification, Validation & Maintenance of Equipment 7.5 Compounding Workflow: SOPs, Workflow Software, Production Queues & Labeling 7.6 Handling, Storing, Packaging, Transporting & Disposing of Finished CSPs
8 Chapter 8: Calculations, Osmolarity & Physicochemical Compatibility
8.1 Sterile Compounding Calculations: Millimoles, Milliequivalents, Osmolarity & Tonicity Adjustments 8.2 Physical and Chemical Incompatibilities: pH Effects, Salt Formations & Precipitation Mechanisms 8.3 Complex Admixture Compatibility: Calcium-Phosphate Solubility Curves & Parenteral Nutrition Dynamics
9 Chapter 9: Therapeutics, Administration & Patient Monitoring
9.1 Patient-Specific Parameters: Verifying CSP Orders 9.2 Special Administration Routes: Epidural, Intrathecal, Ophthalmic & Intravesical Sterile Preparations 9.3 Medication Delivery Devices, Home Infusion & Patient Education 9.4 High-Alert Sterile Medications, Pediatric/Neonatal Considerations & Extravasation Management 9.5 Therapeutic Drug Monitoring, Catheter-Related Bloodstream Infection (CRBSI) Prevention & Clinical Vigilance 9.6 Medication Adherence in Home and Outpatient Sterile Therapy 9.7 Interprofessional Care Coordination for Sterile Preparations
10 Chapter 10: Quality Management, Records & Personnel Competency
10.1 Master Formulation Records (MFR) vs. Compounding Records (CR) Requirements & Workflow 10.2 Personnel Training, Core Competency & Written Testing Requirements 10.3 Gloved Fingertip and Thumb Sampling (GFT) Testing Cadence, Pass/Fail Thresholds & Action Plans 10.4 Media-Fill Testing Protocols: Simulation Design, Incubation Parameters & Failure Investigations 10.5 Standard Operating Procedures & Document Control 10.6 Quality Assurance & Quality Control Programs 10.7 Inspection Methods, Self-Audits & Continuous Readiness 10.8 Literature Evaluation: Research Methods, Statistics & Stability Evidence
11 Chapter 11: Regulatory Oversight, Accreditation & Drug Supply Chain
11.1 Drug Quality and Security Act (DQSA) & FDA Section 503A Traditional Pharmacies vs. Section 503B Outsourcing Facilities 11.2 State Boards of Pharmacy, FDA Guidance & Inter-Agency Regulatory Jurisdictions 11.3 Drug Supply Chain Security Act (DSCSA), Component Qualification & Certificate of Analysis (CoA) Verification 11.4 CMS, The Joint Commission, CDC, ASPEN & ASHP: Standards Beyond USP and FDA
12 Chapter 12: Safety Management, Investigations, Recalls & Waste
12.1 Root Cause Analysis (RCA), CAPA Framework & Out-of-Specification (OOS) Investigations 12.2 Adverse Drug Event Reporting, FDA MedWatch Form 3500 & Product Recall Protocols 12.3 Occupational Safety, Hazardous Waste Disposal (RCRA / EPA) & Spill Clean-up Management
6.2 Release Testing: Sterility (USP <71>), Endotoxin (USP <85>) & Particulates (USP <788>)
Key Takeaways Explain This Topic AI
Sterility testing per USP <71> requires membrane filtration (preferred) or direct inoculation into two media: Fluid Thioglycollate Medium (FTM, 32.5°C) and Soybean-Casein Digest Medium (TSB, 22.5°C) for a mandatory 14-day incubation period.
Method suitability testing (Bacteriostasis/Fungistasis testing) is required prior to relying on USP <71> to confirm that the drug substance does not inhibit microbial growth in the test media.
Bacterial Endotoxin Testing (BET) per USP <85> utilizes Limulus Amebocyte Lysate (LAL) to quantify endotoxins; the endotoxin limit is calculated as K / M K / M K / M , where K = 5.0 EU/kg K = 5.0\,\text{EU/kg} K = 5.0 EU/kg for general parenterals and K = 0.2 EU/kg K = 0.2\,\text{EU/kg} K = 0.2 EU/kg for intrathecal medications.
USP <788> sets subvisible particulate limits: small-volume parenterals ( ≤ 100 mL \le 100\,\text{mL} ≤ 100 mL ) cannot exceed 6,000 particles ≥ 10 μ m \ge 10\,\mu\text{m} ≥ 10 μ m or 600 particles ≥ 25 μ m \ge 25\,\mu\text{m} ≥ 25 μ m per container.
Last updated: September 2026
The Three Pillars of Release Testing
Release testing confirms that a compounded sterile preparation meets its specifications before patients receive it. Under USP <797> Section 12, every CSP is visually inspected , and sterility and endotoxin testing are required when the category and BUD call for them. The three laboratory standards that matter most are:
Sterility Testing (USP <71>) : Confirms absence of viable bacteria and fungi.
Bacterial Endotoxin Testing (USP <85>) : Quantifies pyrogenic lipopolysaccharides.
Particulate Matter Testing (USP <788>) : Sets subvisible particle limits for injections. Compounders use it as a quality benchmark, but USP <797> does not list it as a CSP release test.
When USP <797> Requires Sterility and Endotoxin Testing
- Situation Sterility test Bacterial endotoxin test
- Category 1 Not required Not required
Category 2, Table 13 BUD without testing Not required Should be done for injectables made from nonsterile components
Category 2 with a BUD that requires sterility testing Required Required for injectables made from nonsterile components
Category 3 Required for every batch Required for injectables made from nonsterile components
Batch size: any batch that requires sterility testing is capped at 250 final yield units .
Small batches: if 1 to 39 CSPs are made, extra units equal to 10% of the batch, rounded up , are made for testing (1 CSP needs 1 extra; 39 CSPs need 4 extra). For 40 or more, the sample sizes in USP <71> Table 3 apply.
Methods: USP <71> with its Method Suitability Test, or an alternative validated per USP <1223> that is non-inferior to <71>.
Failures: a failed sterility test starts an investigation that includes identifying the organism and reviewing the test, the facility, the process and the personnel, then deciding whether other CSPs are affected. The investigation and corrective actions must be documented.
Dispensing before results: allowed only with procedures in place to notify the prescriber immediately of a failure, recall unused CSPs, quarantine stock, and check other lots (USP <797> 18.1).
- Sterility Testing per USP General Chapter <71>
- Testing Methods
Membrane Filtration (Preferred Method) : The drug solution is passed through two 0.45 μ m 0.45\,\mu\text{m} 0.45 μ m analytical membrane filter canisters. The filters are rinsed with sterile diluent (Fluid A or D) to wash away antimicrobial drug residues, and media is introduced directly into the closed canisters.
Direct Inoculation : Used only when the drug solution cannot be filtered (e.g., oily suspensions, emulsions). An aliquot of the drug is injected directly into growth media.
Dual Growth Media & Incubation Conditions
Growth Medium Incubation Temperature Target Organisms Mandatory Incubation Duration
Fluid Thioglycollate Medium (FTM) 32.5 ∘ C ± 2.5 ∘ C 32.5^\circ\text{C} \pm 2.5^\circ\text{C} 32. 5 ∘ C ± 2. 5 ∘ C Obligate and facultative anaerobes; mesophilic aerobes 14 days
Soybean-Casein Digest Medium (TSB) 22.5 ∘ C ± 2.5 ∘ C 22.5^\circ\text{C} \pm 2.5^\circ\text{C} 22. 5 ∘ C ± 2. 5 ∘ C Fungi (yeasts and molds); aerobic bacteria 14 days
Important
A passing sterility test can be declared only after the full 14-day incubation . If turbidity or growth appears in either medium during the 14 days, the test fails, unless the laboratory proves the test itself was invalid. The batch is rejected or recalled, and an investigation follows.
Method Suitability (Bacteriostasis and Fungistasis / B&F Testing)
Before a laboratory can perform USP <71> testing on a specific drug formulation, it must conduct Method Suitability Testing . B&F testing inoculates test media containing the drug with low levels ( < 100 CFU < 100\,\text{CFU} < 100 CFU ) of six compendial challenge organisms ( S. aureus , P. aeruginosa , B. subtilis , C. albicans , A. brasiliensis , C. sporogenes ). If the drug inhibits growth, neutralizing agents or enhanced wash volumes must be validated to prevent false-negative sterility tests.
Bacterial Endotoxin Testing (BET) per USP General Chapter <85>
Bacterial endotoxins are heat-stable lipopolysaccharides derived from the outer cell membrane of Gram-negative bacteria. When introduced intravenously or intrathecally, endotoxins bind to macrophage CD14/TLR4 receptors, triggering massive cytokine cascades (fever, septic shock, disseminated intravascular coagulation, death).
The Limulus Amebocyte Lysate (LAL) Reagent
BET utilizes an aqueous extract of circulating blood cells (amebocytes) from the horseshoe crab ( Limulus polyphemus ). When endotoxin encounters LAL enzymes, an enzymatic clotting cascade is initiated:
Gel Clot Assay : Qualitative clotting endpoint (formation of a firm, inverted gel).
Chromogenic Assay : Colorimetric cleavage of a synthetic peptide releasing yellow p p p -nitroaniline.
Turbidimetric Assay : Spectrophotometric measurement of optical turbidity as clotting progresses.
The Compendial Endotoxin Limit Formula
The maximum allowable endotoxin limit ( E L EL E L ) for any parenteral drug is calculated as:
E L = K M EL = \frac{K}{M} E L = M K
Where:
K K K = The threshold pyrogenic human dose of endotoxin per kilogram of body weight:
K = 5.0 EU/kg K = 5.0\,\text{EU/kg} K = 5.0 EU/kg for any parenteral route other than intrathecal .
K = 0.2 EU/kg K = 0.2\,\text{EU/kg} K = 0.2 EU/kg for the intrathecal route (because cerebrospinal fluid is 25 times more sensitive to pyrogenic shock!).
M M M = The maximum recommended human dose of the drug administered per kilogram of body weight within a single 1-hour period (if weight-based dosing is unknown, assume an average adult weight of 70 kg 70\,\text{kg} 70 kg ).
Worked Clinical Example : A patient receives intravenous vancomycin at a maximum dose of 15 mg/kg/hr 15\,\text{mg/kg/hr} 15 mg/kg/hr . What is the endotoxin limit?
E L = 5.0 EU/kg 15 mg/kg = 0.33 EU/mg EL = \frac{5.0\,\text{EU/kg}}{15\,\text{mg/kg}} = 0.33\,\text{EU/mg} E L = 15 mg/kg 5.0 EU/kg = 0.33 EU/mg
Particulate Matter in Injections (USP General Chapter <788>)
Insoluble subvisible particles (silicone droplets, rubber fragments, glass lamellae, cellulose fibers) can cause pulmonary microvascular occlusion and granuloma formation. USP <788> specifies limits using Light Obscuration (LO) particle counters:
Preparation Volume Maximum Particles ≥ 10 μ m \ge 10\,\mu\text{m} ≥ 10 μ m Maximum Particles ≥ 25 μ m \ge 25\,\mu\text{m} ≥ 25 μ m
Small-Volume Parenterals (SVP, ≤ 100 mL \le 100\,\text{mL} ≤ 100 mL ) ≤ 6 , 000 \le 6,000 ≤ 6 , 000 per container ≤ 600 \le 600 ≤ 600 per container
Large-Volume Parenterals (LVP, > 100 mL > 100\,\text{mL} > 100 mL ) ≤ 25 \le 25 ≤ 25 particles per mL ≤ 3 \le 3 ≤ 3 particles per mL
Method Suitability Testing: Overcoming False Negatives in Sterility Testing
Compendial sterility testing is susceptible to false-negative results if the compounded formulation possesses intrinsic antimicrobial or antifungal properties. Under USP <71>, Method Suitability Testing (formerly Bacteriostasis and Fungistasis / B&F testing) must be documented prior to releasing patient batches:
Experimental Design of Method Suitability
Challenge Inoculation : Test aliquots of the drug formulation are inoculated with low inocula (less than 100 CFU) of six reference challenge microorganisms:
- Staphylococcus aureus (Gram-positive aerobe)
- Pseudomonas aeruginosa (Gram-negative aerobe)
- Bacillus subtilis (spore-forming aerobe)
- Clostridium sporogenes (obligate spore-forming anaerobe)
- Candida albicans (yeast)
- Aspergillus brasiliensis (filamentous mold)
Growth Promotion Verification : Parallel control containers containing growth media without drug are simultaneously inoculated with identical challenge organisms.
Acceptance Criteria : Conspicuous growth of all challenge organisms must occur within 3 to 5 days in the presence of the drug, matching control growth rates.
Neutralization and Wash Strategies
When an antibiotic, preservative, or antifungal inhibits microbial replication in test canisters, analysts must validate neutralization strategies:
Membrane Rinsing (Fluid A / Fluid D) : Increasing wash volumes across 0.45-micron filters up to 500 mL per canister to desorb residual drug.
Chemical Inactivation : Adding compendial beta-lactamases (penicillinase) to hydrolyze beta-lactam antibiotics, or polysorbate 80 / lecithin to neutralize phenolic or quaternary ammonium preservatives.